This 2021 editorial by Yng Sun and Cheng-Che E. Lan evaluates the clinical evidence supporting low-level light therapy (LLLT) for dermatological applications. The authors highlight that while LLLT shows promise in areas such as skin rejuvenation, acne treatment, wound healing, body contouring, and androgenic alopecia, many studies suffer from methodological
An in vitro study published in the International Journal of Cosmetic Science (2021) examined the effects of low-level red (660 nm) and near-infrared (850 nm) light therapy on human skin cells, finding that this combination significantly increased the expression of type I collagen and elastin, which are crucial for skin
Photobiomodulation (PBM), also known as low-level light therapy (LLLT), is a nonthermal treatment that uses red and near-infrared light to stimulate cellular processes, enhancing ATP production, modulating reactive oxygen species, and activating transcription factors. This molecular activity promotes tissue repair, reduces inflammation, and supports wound healing, neuroprotection, and cellular regeneration.
This systematic review evaluates the oncologic safety of photobiomodulation (PBM), or low-level light therapy (LLLT), for aesthetic skin rejuvenation, analyzing multiple studies to determine whether PBM poses a risk of inducing or promoting skin cancer. The findings indicate no evidence of increased skin cancer risk, while PBM effectively enhances skin
This review explores the clinical applications of photobiomodulation (PBM), or low-level light therapy (LLLT), in dermatology and regenerative medicine, highlighting its role in enhancing mitochondrial ATP production, modulating oxidative stress, and promoting cell signaling for tissue repair. PBM has shown potential in improving skin appearance, treating acne vulgaris, accelerating wound
A randomized, double-blinded clinical trial investigated the efficacy and safety of low-level light therapy (LLLT) using 660 nm red LEDs and 411 to 777 nm white LEDs for treating facial wrinkles in 52 adult female participants. Over 12 weeks, participants received daily facial irradiation with 5.17 J of either red
